GeoVax Labs (GOVX) Stock Price

GeoVax Labs Price

NASDAQ·CLOSED
0.16
​
Market closed

Revenue has compounded at 5.8% per year over the past 19 years to 2.49 M USD. GeoVax Labs's net margin stands at -862.3%, down from -161.2% several years earlier.

GeoVax Labs stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeoVax Labs business model & stock analysis

GeoVax Labs develops vaccines using its MVA-VLP platform, focusing on HIV, Zika, Ebola, Marburg, Lassa Fever, and cancer immunotherapy. The company's DNA/MVA vaccine regimen targets HIV clade B, while its Tetravalent Vaccine addresses filovirus epidemics. Revenue comes from research and development contracts with government agencies and biotech partners for vaccine development. The firm's products are sold to public health organizations and pharmaceutical companies seeking advanced vaccine solutions. GeoVax's clinical-stage development programs target high-need disease areas, with HIV and filovirus vaccines representing key commercial opportunities. The company's platform enables in vivo expression of non-infectious VLPs, supporting its focus on infectious disease and cancer applications. GeoVax Labs' development pipeline includes HIV, Zika, and hemorrhagic fever vaccines, with the DNA/MVA regimen as its most advanced program. The company generates revenue through grants and partnerships for vaccine development, leveraging its MVA-VLP technology to create novel immunotherapies. Its focus on unmet medical needs drives collaboration with health authorities and industry partners.

Frequently asked questions about GeoVax Labs

8 analysts currently rate the GeoVax Labs stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the GeoVax Labs share trades at 0.15 EUR (0.16 USD).

The GeoVax Labs share (GOVX) is listed on 4 stock exchanges, including: NASDAQ (GOVX), Frankfurt (E8L.F), München (E8L.MU), Düsseldorf (E8L.DU).

The revenue cannot currently be calculated for GeoVax Labs.

The expected profit of GeoVax Labs is -1.07 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of GeoVax Labs is currently -0.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the GeoVax Labs stock.

The P/S cannot be calculated for GeoVax Labs currently.

The Eulerpool Quality Score for GeoVax Labs is 7/10.

The ISIN of GeoVax Labs is US3736787058. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of GeoVax Labs is A2QERV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of GeoVax Labs is GOVX. The ticker symbol is used to trade GeoVax Labs shares on the stock exchange.

Fair ValueTerminal
0.13 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
131,007.63 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website geovax.com
Currency
USD
Initial public offering
Apr 4, 1994
ISIN
US3736787058
Cusip
373678507
Sedol
BMYPNY9
Market capitalization
34,050.75 USDMicro Cap
52-Week Range
PEG
0.00
P/E ratio
P/Ee 2026
-0.01
P/Ee 2027
-0.02
P/Ee 2028
-0.02
P/S
P/Se
—
EV/EBIT
0.10
P/B Ratio
0.01
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-459.80 %
Last updated Nov 4, 2026, 4:05 PM

GeoVax Labs Ticker

DÜSSELDORF · E8L.DUFRANKFURT · E8L.FMUNICH · E8L.MUNASDAQ · GOVX

All fundamentals and in-depth analysis of GeoVax Labs

Our stock analysis for GeoVax Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GeoVax Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.